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Summary
Background: Many studies have suggested that in the era of drug-eluting stents (DES)
one of the causes of in-stent restenosis is stent fracture (SF). Yet there have been
few studies of the major adverse cardiac events and treatment of DES SF.
Methods and results: From September 2003 to May 2008, 3365 patients received
successful stent implantation with DES, of whom 1009 patients underwent a follow-
up coronary angiography irrespective of symptoms. Seventeen SFs were detected in
15/1009 patients (1.5%). All SF patients were continued on medication with com-
bination antiplatelet therapy, regardless of angina symptoms. If in-stent restenosis
at the fractured site was signiﬁcant, we performed coronary interventions even
in patients without ischemic symptoms. Patients were treated with heterogenous
DES for restenosis lesions (5/8 patients), and the rest were treated with either
homogenous DES (2 patients), or plain old balloon angioplasty (1 patient) or medical
treatment (7 patients). None of the SF patients suffered from cardiac death during
a follow-up period of 20.4± 12.3 months.
Conclusion: If patients with SF were continued on combination antiplatelet therapy
irrespective of ischemic sym
cardiac events, especially c
© 2009 Japanese College of
reserved.
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doi:10.1016/j.jjcc.2009.02.010ptoms, there would occur a low rate of major adverse
ardiac death associated with SF.
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ntroduction
rug-eluting stents (DES) have dramatically
educed in-stent restenosis compared to bare-
etal stents (BMS) [1], but post-DES restenosis
emains a problem. Many studies have suggested
hat one of the causes of post-DES restenosis is stent
racture (SF) [2,3]. The SF was usually detected
t a routine follow-up coronary angiography inci-
entally, but some cases were related to in-stent
estenosis or presented with late stent thrombosis
4—7]. Thus, in the era of DES, coronary SF rarely
evelops, but is one of the important problems.
There are few studies about the major adverse
ardiac events after treatment of DES SF. The objec-
ive of the present study was to deﬁne clinical
utcomes, optimal treatment, and major adverse
ardiac events of DES SF.
ethods
ubjects
hree thousand three hundred sixty ﬁve patients
nderwent successful implantation with DES from
eptember 2003 to May 2008 at Chonnam National
niversity Hospital, Gwang-ju, Korea, of whom
009 patients underwent a follow-up coronary
ngiography irrespective of symptoms. The SF
as easily detected on ﬂuoroscopy or angiog-
aphy, but some cases were difﬁcult to detect
nless investigated by careful angiography review
r intravascular ultrasound (IVUS) (Fig. 1). We ret-
ospectively enrolled the patients for study analysis
fter reviewing the initial angiography and medical
ecords.
tent fracture
SF was deﬁned as the complete/incomplete sep-
ration of the stent strut by a ﬂuoroscopic image
nd/or the absence of a stent strut on at least one
lice of IVUS image. We classiﬁed SF into the follow-
ng four types: type I, a single strut fracture only;
ype II, multiple strut fractures at different sites;
ype III, complete transverse SF without displace-
ent of fractured fragments more than 1mm during
he cardiac cycle; type IV, complete transverse lin-
ar type III fracture with stent displacement (Fig. 2)
11,12].rocedure and antiplatelet treatment
ercutaneous coronary intervention (PCI) was
erformed according to standard interventional
f
r
w
a
v423
ethods. The choice of DES was at the discretion of
he operator. All patients who underwent PCI were
reated with aspirin (100—300mg daily) and clopi-
ogrel (75mg daily for at least 6 months). A triple
ntiplatelet regimen including cilostazol was used
n some patients at the operator’s discretion.
ollow-up
he follow-up coronary angiography was performed
t 6—9 months or earlier if they had clinical symp-
oms or evidence of myocardial ischemia after PCI.
ngiographic analysis and deﬁnitions
e compared follow-up coronary angiogram with
ngiogram at the index procedure side by side by
wo independent interventional cardiologists. The
esion type was classiﬁed morphologically according
o American Heart American/Association College of
ardiology (ACC/AHA) classiﬁcation. We measured
ngulation degree of the vessel at the systolic frame
y a protractor. Right coronary artery was measured
t the left anterior oblique view, and left coronary
rtery at the right anterior oblique view. The sever-
ty of the angulation degree was divided into mild
<45◦), moderate (45◦—90◦), or severe (>90◦). In-
tent restenosis (ISR) at repeat angiography was
eﬁned as a diameter stenosis >70% within the
tented segment, or a gap between the stent strut
ormed by a SF. Target lesion revascularization was
eﬁned as treatment for recurrent angina and signs
f ischemia and a >70% diameter stenosis at the tar-
et lesion on follow-up angiography. Major adverse
ardiac events were deﬁned as death, myocardial
nfarction, and target lesion revascularization dur-
ng the hospital stay or at follow-up.
tatistical analysis
ategorical variables are expressed as number and
ercentages of patients. Continuous variables were
resented as mean± SD or median and range val-
es.
esults
n the follow-up coronary angiography in 1009
atients, 17 SFs were detected in 15 patients. Two
atients had two SFs in one stent. The mean times
rom stent implantation to detection of fracture at
epeat angiography was 15.6± 11.6 months. The SF
as veriﬁed by coronary ﬂuoroscopy in 13 patients,
nd detected only by IVUS in 2 patients. The indi-
idual data of SF patients are described in Table 1.
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Figure 1 After predilation of right coronary artery (RCA), intravascular ultrasound showed signiﬁcant neointimal
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cformation and complete stent strut fracture at the point
indicates the stent fracture site. This case was difﬁcult t
the stented segment (arrow heads). Right side of the inse
line represents a schematic diagram of the stent.
Clinical characteristics of patients
The mean age was 59.5± 9.1 years. Number of
male patients was 10 (10/15 patients, 66.7%).
Seven patients had underlying hypertension and 6
had diabetes (46.6%, 40%, respectively). At admis-
sion, their diagnoses were old myocardial infarction
(1 patients, 6.7%), acute myocardial infarction (5
patients, 33.3%), and angina pectoris (9 patients,
60%).
Procedural and angiographic characteristics
The site of SF was most common in right coronary
artery (RCA) (7 patients, 46.6%, 7 lesions, 41.2%),
with a similar number in left anterior descending
artery (LAD) (6 patients, 40%, 7 lesions, 41.2%),
then, left circumﬂex artery (LCx) (2 patients,
13.3%, 2 lesions, 11.8%). The SF pattern was type
III (10 of 17 fractures) and IV (7 of 17 fractures).
Most of the fractured stents were sirolimus-eluting
stents (SES) (13 patients, 86.7%, 15 lesions, 88.2%),
the other were paclitaxel-eluting stents (PES) (2
patients, 13.3%). Mean diameter of fractured stents
was 3.0± 0.2mm and length was 33.0± 0.2mm.
v
b
i
c
phe angiographic stenosis in the distal RCA. Dotted arrow
tect unless investigated by IVUS. (a) A strut-free slice in
hows angiogram of the RCA at ﬁrst post-stenting and the
he mean angulation degree of fractured site was
7.8± 18.3◦, over moderate degree (>45◦) was
patients, 8 lesions. The restenosis at the site
f fracture was associated with majority of SF
atients, with signiﬁcant stenosis (>70%) at the
ractured site in 8 patients (53.3%), 10 lesions
58.8%). The restenosis type was mostly focal (9
esions, 52.9%), only one case was diffuse type (1
esion, 5.8%). Restenosis rate according to SF type
ccurred in 7/10 lesions (70%) in SF type III, 3/7
esions (42.9%) in type IV. There was overlapping
tent in 4 patients (26.7%).
reatment of DES stent fracture and clinical
ollow-up
any SF patients in our study had no angina
ymptoms (8/15 patients, 53.3%), and thus were
ncidentally detected on the routine follow-up
oronary angiography. One patient presented with
ery late stent thrombosis in the fracture site
ecause he stopped medication for 7 days. If
n-stent restenosis at the fractured site was signiﬁ-
ant, we performed coronary interventions even in
atients without ischemic symptoms. In contrast,
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Digure 2 Examples of two different types of stent frac
between black line) without displacement of fractured
rrow). (B) Type IV deﬁned complete transverse linear ty
ven though some patients complained of angina
uring our clinic follow-up, if there was no signiﬁ-
ant restenosis at the fractured site, these patients
ere continued on intensive medical treatment
ncluding combination antiplatelet agents. Patients
ere treated with heterogenous DES for the binary
estenosis lesion (5/8 patients), and the rest were
reated with either homogenous DES (1 SES, 1 PES)
r plain old balloon angioplasty (POBA) (1 patient)
r medical treatment (Fig. 3). All SF patients were
ontinued on medication with dual antiplatelet
herapy (10/15 patients) or triple antiplatelet ther-
py (5 patients) regardless of angina symptoms.rognosis
ix patients underwent follow-up coronary angiog-
aphy after detecting SF. Of these, 3 patients
ontinued on medication alone, and 3 patients
O
w
d
[
i(A) Type III deﬁned complete transverse stent fracture
ments more than 1mm during the cardiac cycle (black
I fracture with stent displacement (black arrow).
ad a stent deployed in the fractured site. In the
ollow-up angiography, none of the patients with
edication alone showed signiﬁcant change, nor
ore aggravated restenosis in the SF lesion com-
ared with previous coronary angiography (Fig. 4).
n 1 patient with stent implantation, there was in-
tent restenosis, but no recurrent fracture. None
f the SF patients suffered from cardiac death dur-
ng a follow-up period of 20.4± 12.3 months after
etection of SF.
iscussionur study demonstrates the occurrence rate of SF
as about 1.5% in the DES. In other reports, the inci-
ence was various (0.84%, 2.6% or 7.7%) in the SES
8—10]. Little is known about the exact incidence
n the ‘‘real-world’’ since repeat angiography was
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tFigure 3 Algorithm for evaluation and optimal treatmen
with; SF, stent fracture; CAG, coronary angiography; Tx,
not performed to all patients who underwent DES
implantation, and in some SF, it is difﬁcult to diag-
nose unless investigated by careful angiography
review, or incidentally identiﬁed by only IVUS. In
our study, the SF was limited to type III/IV. This fact
shows that the identiﬁcation of SF was relatively
difﬁcult in the situation of type I/II [11,12]. There-
fore, we recommend careful angiography review
and/or IVUS at the ISR of DES. In addition, multi-
center trials should be further undertaken.
In the present study, SF occurred mostly in SES,
with only 2 patients in PES, and it was associated
with in-stent restenosis and focal restenosis. These
results are similar to previous studies. Even though
the PES is an open cell design, the SES is a closed
cell design with links connecting the cells, play-
ing an important role in distribution. However, the
a
s
e
r
Figure 4 (A) Two type IV stent fractures in one stent (whi
the follow-up angiography 1 year later, there was no signiﬁca
fracture site (white arrow) compared with previous coronarypatients having coronary stent fracture. a/w, associated
tment; IVUS, intravascular ultrasound.
inks are thinner than the frame of the cell and the
inks are thought to be vulnerable to fracture if the
tent receives excessive stress [1]. However, two
Fs were observed in PES patients. Both fractures
ere developed in distal RCA, but the stent lengths
ere 64mm and 24mm, with no signiﬁcant differ-
nces in other factors compared with SES fractures.
n our opinion, PES fracture occurred due to the
ocation receiving strong motion such as occurs in
istal RCA. SF may represent a potential mecha-
ism for restenosis in DES: local under-dosage due
o the SF in combination with mechanical irrita-
ion is the most probable cause of focal restenosis
ssociated with SF [2,3]. Similarly, our results
howed association with in-stent restenosis. But
ven though the majority of fractures related to
estenosis at the fractured site, the restenosis was
te arrow), but there was no signiﬁcant stenosis. (B) In
nt change, nor more aggravated restenosis in the stent
angiography.
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ot always signiﬁcant. We thought that SF with
evere displacement would be more associated with
evere restenotic lesions. Interestingly, signiﬁcant
estenosis occurred more in SF type III [7/10 lesions
70.0%)] than type IV [3/7 lesions (42.9%)]. Insignif-
cant restenosis lesions were not treated with any
ntervention. Even though SF type IV was worse
orphology than type III, target lesion revascu-
arization and binary restenosis more frequently
ccurred in type III.
In some case reports, late stent thrombosis
eveloped in the site of SF and/or coronary
neurysm [4—7]. Previous studies have postulated
hat exposure of a free metal strut protruding into
he vessel lumen clearly could trigger platelet acti-
ation and resultant stent thrombosis. SF could
nvolve partial or complete breakage of the stent,
he latter event may cause immediate ﬂow obstruc-
ion, thrombosis, and myocardial infarction [5]. In
he present study, 1 patient presented with very
ate stent thrombosis in the fracture site because
he patient stopped medication for 7 days. Except
or this patient with poor medication compliance,
here was no patient with stent thrombosis. So
e could carefully suggest that if SF patients
ere continued on medication with dual or triple
ntiplatelet agents, there would be a very low rate
f major adverse cardiac events (post-detection
f stent fracture) including stent thrombosis asso-
iated with SF. But continued medication with
ombination antiplatelet agents is very hard during
hole life in the real-world. The appropriate dura-
ion of combination antiplatelet therapy is needed
ollowing SF. In the aspect of DES SF treatment, if
n-stent restenosis at the fractured site was signif-
cant, we performed coronary interventions even
n patients without ischemic symptoms. And we
mplanted mostly heterogenous stent, performed
lain old balloon angioplasty in one case. In the
linical follow-up, there was no cardiac symptom
r event during 20.4± 12.3 months. However, opti-
al and detailed strategies should be investigated
or SF.
tudy limitations
irst, this was a retrospective single-center study,
o is subject to limitations inherent in this type
f clinical investigation. Second, the number of
atients was small. Thus, some selection bias can-
ot be excluded entirely. Third, because follow-up
ngiographic data were not available in every
atient who underwent DES implantation, an accu-
ate frequency of DES fracture could not be
btained.
[[428
Conclusions
Of the patients with SF, coronary intervention was
performed only when the binary restenosis lesion
was signiﬁcant. During follow-up, patients with SF
have continued on combination antiplatelet ther-
apy. There is a very low rate of major adverse
cardiac events (post-detection of SF), especially
cardiac death associated with SF.
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